Summary
Carnosine is a dipeptide of beta-alanine and histidine that the body makes and stores in muscle and brain, where it buffers acid, chelates metals, and quenches reactive carbonyls. Small randomized trials and a 2020 meta-analysis of histidine containing dipeptides show modest improvements in fasting glucose, HbA1c, and waist circumference, and a 2016 pilot found 2 g per day prevented worsening insulin resistance in overweight adults, but no trial shows hard clinical outcomes. It is sold lawfully as a dietary supplement in the United States, is not prohibited by WADA, and has not been reviewed as a drug by FDA.
What is Carnosine?
Carnosine is a naturally occurring dipeptide (beta-alanine plus histidine) concentrated in skeletal muscle and brain; sold as a dietary supplement. It is also known as L-carnosine, Beta-alanyl-L-histidine, Histidine containing dipeptide, Beta-alanine (its rate limiting precursor).
How does it work?
Carnosine buffers hydrogen ions inside muscle fibers during intense exercise, chelates transition metals such as copper and zinc, scavenges reactive oxygen species, and forms adducts with reactive aldehydes and sugars, which reduces advanced glycation and lipoxidation end products. It also modulates calcium handling in muscle. The enzyme carnosinase breaks it down rapidly in human blood, so oral carnosine raises tissue levels less efficiently than its precursor beta-alanine. These mechanisms are well described in the 2013 Physiological Reviews article.
| Cluster | Longevity and mitochondrial |
|---|---|
| Routes | Oral capsule or powder (dietary supplement); Oral beta-alanine as a precursor; Eye drops (N-acetylcarnosine, marketed without strong evidence) |
| Conditions studied | Obesity and chronic weight management; Type 2 diabetes; Longevity and healthy aging; Insulin resistance and prediabetes |
| Record | v3, draft, verified Sep 22, 2026 |
What does the evidence say about Carnosine?
Several small randomized trials and meta-analyses. De Courten et al. 2016 randomized 30 overweight, non-diabetic adults to carnosine 2 g per day or placebo for 12 weeks: insulin resistance and 2 hour glucose worsened on placebo but not on carnosine, with no weight change. Menon et al. 2020 pooled randomized trials of histidine containing dipeptides and found reductions in fasting glucose, HbA1c, and waist circumference, mostly in people with metabolic disease. Saadati et al. 2024 pooled trials and found reductions in some inflammatory and oxidative stress markers. Beta-alanine supplementation raises muscle carnosine by 40% to 60% and modestly improves high intensity exercise capacity (Hill 2007). No trial has measured cardiovascular events, diabetes incidence, or mortality.
| Evidence type | Indexed studies | Participants (human) |
|---|---|---|
| Human randomized trials | 4 | 55 |
| Human observational studies | 0 | n/a |
| Animal studies | 0 | n/a |
| All indexed studies | 4 | 55 |
Human evidence
De Courten 2016: 30 overweight or obese adults without diabetes, 2 g carnosine daily versus placebo for 12 weeks; carnosine prevented the rise in fasting insulin, insulin resistance, and 2 hour glucose seen on placebo, with no change in weight or body fat. Menon 2020 meta-analysis of randomized trials of carnosine and related dipeptides: significant reductions in fasting glucose, HbA1c, and waist circumference, with no consistent effect on lipids or blood pressure. Saadati 2024 meta-analysis: reductions in tumor necrosis factor alpha and malondialdehyde across pooled trials. Hill 2007: 4 weeks of beta-alanine (up to 6.4 g per day) raised muscle carnosine by about 60% and improved total work done in a cycling capacity test.
Animal evidence
Rodent studies show carnosine reduces advanced glycation end products, protects against diabetic kidney and vascular changes, improves outcomes after ischemic brain injury, and, in some strains, extends life span, as reviewed by Boldyrev et al. 2013. Rodents have far less serum carnosinase than humans, so oral carnosine reaches tissues more effectively in animals than in people.
Key studies
| Study | Design and population | Outcome | Grade |
|---|---|---|---|
| Effects of carnosine supplementation on glucose metabolism: pilot clinical trial2016 PMID 27040154 | Randomized, double blind, placebo controlled pilot trial, 12 weeksn = 30 Overweight or obese adults without diabetes | Carnosine 2 g per day prevented the rise in fasting insulin, insulin resistance, and 2 hour glucose seen on placebo; no change in body weight | Evidence: Human RCT evidence |
| Histidine-containing dipeptides reduce central obesity and improve glycaemic outcomes: a systematic review and meta-analysis of randomized controlled trials2020 PMID 31828942 | Systematic review and meta-analysis of randomized trialsAdults in randomized trials of carnosine, anserine, or beta-alanine | Significant reductions in fasting glucose, HbA1c, and waist circumference; no consistent effect on lipids or blood pressure | Evidence: Human RCT evidence |
| Effects of carnosine and histidine-containing dipeptides on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis2024 PMID 38086332 | Systematic review and meta-analysis of randomized trialsAdults in randomized trials of carnosine and related dipeptides | Reductions in tumor necrosis factor alpha and malondialdehyde; other markers not consistently changed | Evidence: Human RCT evidence |
| Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity2007 PMID 16868650 | Randomized, placebo controlled supplementation trial, 4 to 10 weeksn = 25 Physically active men | Beta-alanine raised muscle carnosine by about 60% at 4 weeks and 80% at 10 weeks and increased total work done in a cycling capacity test | Evidence: Human RCT evidence |
Conditions studied
| Condition | Grade | Note |
|---|---|---|
| Obesity and chronic weight management | Not graded | GLP-1 based peptides are the only peptides with large randomized trials for weight loss. Semaglutide 2.4 mg produced 14.9% mean weight loss over 68 weeks and tirzepatide 15 mg produced 20.9% over 72 weeks. Retatrutide, cagrilintide, and survodutide are in late stage trials. |
| Type 2 diabetes | Not graded | Several peptide drugs are FDA approved for type 2 diabetes, including insulin, GLP-1 receptor agonists, tirzepatide, and pramlintide. GLP-1 agonists and tirzepatide lower HbA1c by about 1 to 2 percentage points and reduce weight; semaglutide also reduces cardiovascular events. |
| Longevity and healthy aging | Not graded | No peptide has been shown to extend human lifespan. MOTS-c, humanin, and SS-31 (elamipretide) are mitochondrial peptides with rodent data and, for elamipretide, human trials in mitochondrial myopathy and Barth syndrome. Epitalon and FOXO4-DRI rest on animal or in vitro data. GLP-1 agonists have the strongest human outcome data for mortality relevant endpoints, through cardiovascular risk reduction. |
| Insulin resistance and prediabetes | Evidence: Human RCT evidence | A 30 person pilot trial found carnosine 2 g daily prevented the rise in fasting insulin and insulin resistance seen on placebo; not a regulated drug. |
Is Carnosine legal in the United States?
FDA and compounding status
Carnosine is regulated as a dietary supplement under the Dietary Supplement Health and Education Act and is not an FDA approved drug; it has not been reviewed by FDA as a drug and has no Pharmacy Compounding Advisory Committee history. Oral products are lawfully sold over the counter. Injectable carnosine is not an approved product, and any injectable version would need a 503A bulks listing to be compounded lawfully.
WADA status
Not WADA prohibited. Not named on the current prohibited list. Athletes should still confirm against the list in force for their season.
Regulatory timeline
No regulatory events recorded.
What published studies of Carnosine used
Ranges below are reported from published studies and labeling only. PeptideAgent does not recommend doses or protocols.
Randomized trials used oral carnosine 2 g per day for 12 weeks (De Courten 2016) and 0.5 to 2 g per day across pooled trials (Menon 2020). Beta-alanine trials used 3.2 to 6.4 g per day for 4 weeks to raise muscle carnosine (Hill 2007).
Routes reported
| # | Route |
|---|---|
| 1 | Oral capsule or powder (dietary supplement) |
| 2 | Oral beta-alanine as a precursor |
| 3 | Eye drops (N-acetylcarnosine, marketed without strong evidence) |
What are the side effects and interactions of Carnosine?
Side effects
| # | Reported side effect |
|---|---|
| 1 | Generally well tolerated in trials at 2 g per day |
| 2 | Mild gastrointestinal upset reported occasionally |
| 3 | Beta-alanine (the precursor) causes dose dependent tingling (paresthesia) |
| 4 | Long term safety beyond several months has not been formally studied |
Interactions
| # | Interaction |
|---|---|
| 1 | No clinically significant interactions documented |
| 2 | Theoretical additive glucose lowering with diabetes medications, given trial effects on glucose (monitor) |
| 3 | Carnosine chelates copper and zinc; separating it from mineral supplements is a theoretical precaution |
Contraindications
| # | Contraindication |
|---|---|
| 1 | Known hypersensitivity to carnosine or beta-alanine |
| 2 | Pregnancy and breastfeeding (no data at supplemental doses) |
How do people access Carnosine legally?
Typical cost: Roughly 15 to 40 USD per month for oral carnosine at 1 to 2 g per day; beta-alanine is roughly 10 to 25 USD per month.
Verified access options
Step 1
Over the counter dietary supplement, no prescription needed.
Step 2
Beta-alanine supplements as a precursor for raising muscle carnosine.
Access paths are verified against public regulatory records and prescriber licensing. We never list unlicensed vendors.
Compare Carnosine
What's actually offered, and what that means for you
Licensed compounding pharmacies, clinics, and telehealth prescribers openly offer many unapproved peptides, and prescribers write prescriptions for them. That does not make carnosine lawful. Carnosine is not FDA approved and not on the 503A bulks list, so a pharmacy has no lawful basis to compound it. [7] [8]
Enforcement is uneven. FDA mostly acts through warning letters to compounders and online sellers, Category 2 safety listings, and import alerts that let it detain shipments, rather than stopping every pharmacy. State pharmacy boards oversee pharmacies day to day, and their rules differ. [8] [9] [10] [11] [12]
What changes for you
- No FDA review of the product: FDA does not check a compounded drug's safety, effectiveness, or quality before it is sold. [12]
- Identity, purity, sterility, and dose accuracy can vary from batch to batch. [8]
- Insurance rarely covers it, so you usually pay cash.
What to check
These checks lower some risks, but they do not make an unlawfully compounded product lawful or safe. Check for:
- A 503A pharmacy licensed in your state (your state board of pharmacy publishes license lookups). [12]
- A real evaluation by a licensed prescriber, not just an online form.
- A certificate of analysis for the specific batch.
Frequently asked questions
Is carnosine legal and safe to take?
Yes. Carnosine is a naturally occurring dipeptide sold lawfully as a dietary supplement in the United States. Randomized trials at 2 g per day for 12 weeks reported no serious adverse effects, and the main complaint with its precursor beta-alanine is harmless tingling. It is not an FDA approved drug and no long term safety trial exists. [1] [4]
Does carnosine help with blood sugar or diabetes?
Modestly, in small trials. In 30 overweight adults, 2 g per day for 12 weeks prevented the worsening of insulin resistance and 2 hour glucose seen on placebo. A 2020 meta-analysis of randomized trials found reductions in fasting glucose, HbA1c, and waist circumference. No trial has shown fewer diabetes diagnoses or complications, so it is not a substitute for standard treatment. [1] [2]
Is carnosine an anti-aging supplement?
The rationale is that carnosine blocks glycation and oxidative damage, and rodent studies show reduced advanced glycation end products and, in some strains, longer life. In humans, trials show lower markers of inflammation and oxidative stress but no evidence of slower aging, and because human blood breaks carnosine down quickly, oral doses reach tissues less efficiently than in rodents. [3] [5]
What are the side effects of carnosine?
Few. Trials at 2 g per day reported occasional mild stomach upset and nothing serious. Beta-alanine, which people take to raise muscle carnosine, causes dose dependent tingling of the skin that fades within an hour and is not harmful. Safety beyond a few months of use has not been formally studied. [1] [4]
How is carnosine taken?
As oral capsules or powder, typically 1 to 2 g per day in trials. Because serum carnosinase degrades it quickly, athletes usually take beta-alanine (3.2 to 6.4 g per day for several weeks) instead, which raised muscle carnosine by about 60% in a 2007 study. Injectable carnosine has no established role. [2] [4]
Is carnosine banned by WADA?
No. Carnosine and beta-alanine are not listed in any section of the WADA Prohibited List as of 2026. Beta-alanine is widely used by athletes as a lawful buffering supplement. As with all supplements, contamination is the practical doping risk, so third party tested products are advisable. [4] [6]
Carnosine vs beta-alanine: which should I take?
For raising muscle carnosine and buffering exercise acid, beta-alanine is better supported because oral carnosine is largely broken down in the blood before reaching muscle. For the glycemic and waist effects seen in metabolic trials, the studies used carnosine itself at 0.5 to 2 g per day. They are not interchangeable, and neither has outcome data beyond biomarkers and exercise tests. [2] [4] [5]
Decisions about starting, stopping, or combining any treatment belong with a licensed clinician who knows your history.
Sources
Numbered citations above point to these primary sources. PubMed entries link to the indexed abstract.
- [1]de Courten B et al. Effects of carnosine supplementation on glucose metabolism: pilot clinical trial. Obesity (Silver Spring) 2016PubMed 27040154, 2016
- [2]Menon K et al. Histidine-containing dipeptides reduce central obesity and improve glycaemic outcomes: a systematic review and meta-analysis of randomized controlled trials. Obes Rev 2020PubMed 31828942, 2020
- [3]Saadati S et al. Effects of carnosine and histidine-containing dipeptides on biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis. Nutr Rev 2024PubMed 38086332, 2024
- [4]Hill CA et al. Influence of beta-alanine supplementation on skeletal muscle carnosine concentrations and high intensity cycling capacity. Amino Acids 2007PubMed 16868650, 2007
- [5]Boldyrev AA, Aldini G, Derave W. Physiology and pathophysiology of carnosine. Physiol Rev 2013PubMed 24137022, 2013
- [6]WADA Prohibited ListWADA, 2026
- [7]FDA: Bulk drug substances used in compounding under section 503A of the FD&C ActFDA
- [8]FDA: Certain bulk drug substances for use in compounding may present significant safety risks (Category 2)FDA
- [9]FDA: Compounding inspections, recalls, and other actions (warning letters to compounders)FDA
- [10]FDA warning letters database: July 30, 2019 letter to a 503A pharmacy that compounded BPC-157 acetate outside section 503AFDA, 2019
- [11]FDA Import Alert 66-41: Detention without physical examination of unapproved new drugs promoted in the U.S. (includes peptide entries)FDA
- [12]FDA: Compounding and the FDA, questions and answersFDA
Cite this page
Free to cite and quote with a link. Data is licensed CC BY 4.0 with attribution to PeptideAgent.
- APA style
PeptideAgent. (2026, September 22). Carnosine: evidence, legality, and access. https://peptideagent.ai/peptides/carnosine- HTML link
<a href="https://peptideagent.ai/peptides/carnosine">Carnosine: evidence, legality, and access</a>, PeptideAgent, updated September 22, 2026.